Shopping Cart
Remove All
Your shopping cart is currently empty
BMS-214662 is a selective farnesyl transferase inhibitor with antitumor activity, useful in studies of pancreatic, head and neck, and lung cancers.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $2,270 | 10-14 weeks | 10-14 weeks | |
| 50 mg | $2,980 | 10-14 weeks | 10-14 weeks | |
| 100 mg | $4,000 | 10-14 weeks | 10-14 weeks |
| Description | BMS-214662 is a selective farnesyl transferase inhibitor with antitumor activity, useful in studies of pancreatic, head and neck, and lung cancers. |
| Targets&IC50 | KRas:8.4 nM, H-Ras:1.3 nM |
| In vitro | BMS-214662 is a potent selective farnesyl transferase (FTI) inhibitor with antitumor activity. [2] BMS-214662 (250 nM, 24h) induces mitochondrial apoptosis in chronic myelogenous leukemia (CmL) stem/progenitor cells, including CD34+38- cells, by activating protein kinase Cbeta. [1] |
| In vivo | HCT-116 xenograft mice, BMS-214662 (250 mg/kg intravenously,300 mg/kg or 400 mg/kg orally), induced tumor cell apoptosis. For HCT-116 and EJ-1 tumors, the doses of BMS-214662 required to kill 90% of cloned tumor-forming cells were approximately 75 and 100 mg/kg, respectively. [3] |
| Synonyms | BMS214662 |
| Molecular Weight | 489.61 |
| Formula | C25H23N5O2S2 |
| Cas No. | 195987-41-8 |
| Smiles | C([C@H]1N(S(=O)(=O)C2=CC=CS2)CC=3C(N(CC4=CN=CN4)C1)=CC=C(C#N)C3)C5=CC=CC=C5 |
| Relative Density. | 1.45 g/cm3 (Predicted) |
| Color | Yellow |
| Appearance | Viscous |
| Storage | store at low temperature | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: < 1 mg/mL (insoluble) DMSO: 80 mg/mL (163.4 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (6.74 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.